The Value of the 8th Edition of American Joint Committee on Cancer Pathological Prognostic Staging on the Selection of Postmastectomy Radiotherapy for T1–2N1 Breast Cancer

• Published in: Journal of oncology Vol. 2022; pp. 7550323 - 11
• Main Authors: Wang, Jun, Zhong, Xiao-rong, Luo, Ting, Xiang, Zhong-zheng, Zeng, Yuan-yuan, Yang, Tian, Zheng, Hong, Liu, Lei
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi 25.10.2022; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Committees; Endocrine therapy; Information management; Mastectomy; Medical prognosis; Metastasis; Patients; Radiation therapy; Radiotherapy; Surgery; China
• ISSN: 1687-8450; 1687-8450; 1687-8469
• DOI: 10.1155/2022/7550323

Background and Objective. The value of postmastectomy radiotherapy (PMRT) in T1-2N1M0 breast cancer remains unclear. Our cohort study is aimed at evaluating the PMRT guiding value of the 8th American Joint Committee on Cancer (AJCC) pathological prognostic staging system in the era of modern systematic treatment in this disease. Methods and Materials. Patients diagnosed with pT1-2N1M0 breast cancer between 2008 and 2018 in West China Hospital, Sichuan University were included. Locoregional-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), breast cancer-specific survival (BCSS), and overall survival (OS) were defined as endpoints. The propensity score matching (PSM), receiver operating characteristic (ROC) curve, the Kaplan-Meier analysis, and the Cox multivariable model were used for data analysis. Results. We identified 1,615 patients with T1-2N1M0 breast cancer, and 44.9% (n=744) of them were treated with PMRT. With a median follow-up of 76 months, 46 (2.8%) recurrences, 96 (5.9%) deaths, and 80 (5.0%) breast cancer-related deaths occurred. The 5-year LRFS, DMFS, DFS, BCSS, and OS were 98.6%, 95.3%, 93.7%, 96.5%, and 96.0%, respectively. PMRT could not improve 5-year LRFS, DMFS, DFS, BCSS, and OS compared with non-PMRT neither before nor after PSM in the era of contemporary systemic treatment. ROC curve showed that the 8th pathological prognostic staging had better discriminative ability compared with the 7th anatomical staging [the area under the curve (AUC) 0.653 vs. 0.546, P<0.001]. In the anatomical staging system, PMRT had comparable 5-year BCSS in comparison with non-PMRT both in stages IIA (97.4% vs. 96.8%, P=0.799) and IIB (95.3% vs. 97.0%, P=0.071). When stratified according to the pathological staging, PMRT was associated with better 5-year BCSS in stage IIB (97.1% vs. 90.7%, P=0.039), while not in stages IA, IB, IIA, and IIIA. Multivariate analysis demonstrated that PMRT was a significantly protective factor for BCSS in stage IIB (HR 0.331, 95% CI: 0.100-0.967, P=0.044). Conclusion. The new staging could better select high-risk patients with T1-2N1 breast cancer for radiotherapy compared with the 7th staging, and PMRT might be exempted except the 8th staging of IIB in the era of contemporary systemic therapy in this disease.